Etho-Testosterone 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Usage

1. Confirm your current training phase on the calendar before drawing: blast doses require 0.67–1.0 ml per injection while cruise doses use 0.17–0.25 ml — knowing the target volume before you begin eliminates measurement errors.
2. Inspect the Beligas 10 ml vial visually under good lighting before every draw; the oil should be clear to pale yellow with no visible particulates or cloudiness.
3. Warm the vial briefly in the palm of your hand for 30–60 seconds if stored below 20 °C to lower viscosity and ease aspiration through the draw needle.
4. Use a 21–23 G needle to draw the measured volume into a 1 ml or 3 ml luer-lock syringe, then swap to a fresh 23–25 G needle for intramuscular injection (gluteal or lateral deltoid are preferred sites for oil volumes up to 1 ml).
5. Administer injections on a consistent twice-weekly schedule appropriate to your phase — for example Tuesday and Friday — to maintain even serum-level troughs regardless of whether you are blasting or cruising.
6. Log each injection date, volume, and site in a training journal; cross-reference with your next bloodwork panel to track haematocrit, total testosterone, and SHBG trends across the full cruise-and-blast calendar.

Warnings

Frequently asked questions

What exactly does a cruise and blast protocol involve with Testosterone Enanthate?

A cruise and blast protocol cycles between a high-dose blast phase — typically 400–600 mg of Testosterone Enanthate per week for 8–12 weeks — and a lower-dose cruise phase at or near replacement levels (100–150 mg/week) for 4–8 weeks. The enanthate ester's multi-day release profile suits both phases from the same vial, requiring only a volume adjustment rather than a compound switch.

How long should the cruise phase last before starting another blast?

Most experienced athletes run cruise phases of four to eight weeks, long enough for HPTA suppression to ease partially and for inflammatory markers to normalise before the next escalation. Shorter cruises of under four weeks offer insufficient recovery time, while cruises beyond twelve weeks begin to resemble a standard cycle gap. Individual bloodwork — specifically LH, FSH and haematocrit — should guide the exact duration.

What signals indicate it is time to transition from blast back to cruise?

Common transition triggers include the end of a pre-planned blast calendar, haematocrit rising above 52%, blood pressure trending outside the normal range, or joint/tendon stress that suggests a recovery period is warranted. Some athletes use a fixed-calendar approach (e.g. 10 weeks blast / 6 weeks cruise), while others use biomarker-led switching based on quarterly bloodwork panels.

How should the Beligas Etho-Testosterone 10ml vial be stored after the first draw?

After the first puncture, store the vial upright at room temperature (15–25 °C / 59–77 °F), away from direct light and heat. Refrigeration is not required but is acceptable; if refrigerated, allow the oil to warm to room temperature before drawing to reduce viscosity. Multi-dose vials should be discarded 28 days after first use or sooner if any cloudiness or particulate matter is observed.

Can a standard insulin syringe be used to draw from the Beligas 10ml vial at cruise-phase doses?

Insulin syringes (0.5 ml or 1 ml capacity) are not recommended for drawing oil-based preparations at 300 mg/ml because the fine gauge (28–31 G) makes aspiration of a viscous oil extremely slow and risks syringe-barrel deformation under suction pressure. A 21–23 G draw needle is appropriate for filling the syringe from the vial; the needle can then be swapped to a 23–25 G injection needle for administration at cruise-range volumes of 0.17–0.25 ml. (2) angle_used

Manufacturer

Beligas Pharmaceuticals sources the active pharmaceutical ingredient in Etho-Testosterone — Testosterone Enanthate — from verified API manufacturers operating under current Good Manufacturing Practice certification. Raw-material procurement at Beligas follows a defined vendor-qualification programme: each API lot is subjected to identity confirmation via spectroscopic analysis and purity assessment before it is accepted into the production workflow. This upstream sourcing discipline is the first critical control point in Beligas's quality chain and directly determines the assay result obtained in the finished-product HPLC release test. Beligas maintains documentation traceability from API certificate of analysis through to the released vial, enabling batch-level recall capability should any out-of-specification result emerge post-release. The 300 mg/ml concentration of Etho-Testosterone reflects a deliberate formulation decision: the API load and carrier-oil ratio were optimised to remain injectable at room temperature while delivering a clinically meaningful dose per millilitre across the full range of cruise and blast volumes.